Literature DB >> 6628530

Displacement of lidocaine from serum alpha 1-acid glycoprotein binding sites by basic drugs.

D L Goolkasian, R L Slaughter, D J Edwards, D Lalka.   

Abstract

Since little is known of the number and types of binding sites on alpha 1-acid glycoprotein (AAG) and because drug-drug protein binding interactions often fail to fit a simple model, a study of the effect of 9 known AAG binding drugs on lidocaine free fraction (LFF) was performed. Serum was obtained from 10 healthy males, pooled and various concentrations (from 0.15 to 1000 micrograms/ml) of amitriptyline, bupivacaine, chlorpromazine, disopyramide, imipramine, meperidine, nortriptyline, propranolol and quinidine were added. LFF was determined by equilibrium dialysis at an initial lidocaine concentration of 2.0 micrograms/ml. LFF increased from 0.30 +/- 0.019 (mean +/- SD) in the absence of displacing agents to maximum values ranging from 0.59 (nortriptyline) to 0.73 (bupivacaine). Plots of LFF vs. the logarithm of displacing drug concentration yielded simple sigmoidal curves in all cases. LFF was increased 50% by an initial bupivacaine concentration of 6.0 micrograms/ml with all other drugs requiring more than 10 micrograms/ml to increase LFF to that extent. Lidocaine binding in a 4.5 g/dl albumin solution was unaffected by concentrations of quinidine, meperidine, nortriptyline and bupivacaine up to 200 micrograms/ml. Addition of AAG to serum reduced LFF as expected. A plot of the reciprocal of bound drug concentration vs. the reciprocal of free drug concentration in the presence and absence of quinidine suggested a competitive binding interaction. These data indicate that the binding interactions between lidocaine and the various displacing compounds are not significantly complicated by cooperative effects and that, with the possible exception of bupivacaine, displacement of lidocaine by any of these drugs is likely to be of clinical significance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6628530     DOI: 10.1007/bf01037957

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  24 in total

1.  Serum albumin and lipoproteins as the quinidine binding molecules in normal human sera.

Authors:  O G Nilsen
Journal:  Biochem Pharmacol       Date:  1976-05-01       Impact factor: 5.858

2.  Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

Authors:  K M Piafsky; O Borgå
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

Review 3.  Binding of drugs by albumin and plasma protein.

Authors:  J J Vallner
Journal:  J Pharm Sci       Date:  1977-04       Impact factor: 3.534

4.  Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction.

Authors:  P A Routledge; W W Stargel; G S Wagner; D G Shand
Journal:  Ann Intern Med       Date:  1980-11       Impact factor: 25.391

5.  Simultaneous determination of bupivacaine and 2,6-pipecoloxylidide in serum by gas-liquid chromatography.

Authors:  L J Lesko; J Ericson; G Ostheimer; A Marion
Journal:  J Chromatogr       Date:  1980-05-09

6.  Binding of quinidine in sera with different levels of triglycerides, cholesterol, and orosomucoid protein.

Authors:  O G Nilsen; P Leren; I Aakesson; S Jacobsen
Journal:  Biochem Pharmacol       Date:  1978-03-15       Impact factor: 5.858

7.  Meperidine binding in maternal and fetal plasma.

Authors:  R L Nation
Journal:  Clin Pharmacol Ther       Date:  1981-04       Impact factor: 6.875

8.  Optical studies on the specific interaction of dipyridamole with alpha 1-acid glycoprotein (orosomucoid).

Authors:  S El-Gamel; U Wollert; W E Müller
Journal:  J Pharm Pharmacol       Date:  1982-03       Impact factor: 3.765

9.  Mechanisms of nonlinear disposition kinetics of sulfamethazine.

Authors:  P du Souich; D Lalka; R Slaughter; A T Elvin; A J McLean
Journal:  Clin Pharmacol Ther       Date:  1979-02       Impact factor: 6.875

10.  The use of a selected ion monitoring technique to study the disposition of bupivacaine in mother, fetus, and neonate following epidural anesthesia for cesarean section.

Authors:  P M Kuhnert; B R Kuhnert; J M Stitts; T L Gross
Journal:  Anesthesiology       Date:  1981-12       Impact factor: 7.892

View more
  7 in total

1.  Lack of effect of treatment with human recombinant-tumour necrosis factor (HrTNF) on the binding of quinidine to alpha 1-acid glycoprotein (AGP).

Authors:  J A Barnett; D E Brenner; P J Creaven; D Lalka
Journal:  Br J Clin Pharmacol       Date:  1989-02       Impact factor: 4.335

2.  Interaction of mixed micelles formed from glycocholic acid and lecithin with the protein binding of various drugs.

Authors:  T W Guentert; S Oie; L Paalzow; B M Frey; R Brandt; L J Aarons; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of pethidine: 1982.

Authors:  D J Edwards; C K Svensson; J P Visco; D Lalka
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

4.  Analysis of lidocaine interactions with serum proteins using high-performance affinity chromatography.

Authors:  Sony Soman; Michelle J Yoo; Yoon Jeong Jang; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-01-25       Impact factor: 3.205

Review 5.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

6.  On-column entrapment of alpha1-acid glycoprotein for studies of drug-protein binding by high-performance affinity chromatography.

Authors:  Jeanethe Anguizola; Cong Bi; Michelle Koke; Abby Jackson; David S Hage
Journal:  Anal Bioanal Chem       Date:  2016-06-11       Impact factor: 4.142

7.  Protein binding and disposition of lignocaine in the elderly.

Authors:  B Cusack; K O'Malley; J Lavan; J Noel; J G Kelly
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.